Wording clarified in Type 2 Diabetes Mellitus therapeutics review, impacting GLP-1 RA DD01 description

Scientific reviews are crucial for synthesizing complex information, especially in rapidly evolving fields like Type 2 Diabetes Mellitus (T2DM) therapeutics. Accurate and unambiguous language is paramount to ensure proper understanding of novel treatments and ongoing clinical trials. This corrigendum addresses minor phrasing ambiguities in a prior narrative review, highlighting the continuous effort to maintain clarity in scientific communication regarding new therapeutic agents and their mechanisms.

The authors identified and revised unclear phrases and expressions within their previously published narrative review, 'Modern-Day Therapeutics and Ongoing Clinical Trials against Type 2 Diabetes Mellitus'. The corrections focused on improving readability and ensuring accurate conveyance of the intended meaning. An example correction involved rephrasing 'fatty liver ailment' to 'fatty liver disorder' in the section discussing the GLP-1 Receptor Agonist DD01.

The authors found that certain phrases and expressions in their original narrative review were unclear, potentially affecting readability. These ambiguities were identified and subsequently revised to enhance clarity and ensure the accurate communication of scientific information.

Specifically, in section 4.1.3. GLP-1 Receptor Agonist, the phrase 'fatty liver ailment' was corrected to 'fatty liver disorder' when describing the therapeutic effects of DD01 against hepatic steatosis and body weight reduction in T2DM patients. The authors explicitly stated that these revisions did not alter the original article's results, interpretations, or conclusions, emphasizing that the core scientific content remained unchanged, only its presentation was refined.